Phase 4 — Post-approval study. The treatment has been approved, but researchers continue monitoring it in a large population over time.
(13 sites) China
Peking University people s hospital /ID# 265493, Beijing, Beijing Municipality Peking University Third Hospital /ID# 243994, Beijing, Beijing Municipality Beijing Tongren Hospital Affiliated To Capital Medical University /ID# 244055, Beijing, Beijing Municipality The First Affiliated Hospital Of Fujian Medical University /ID# 244004, Fuzhou, Fujian Xiamen Eye Center of Xiamen University /ID# 244000, Xiamen, Fujian The Second Affiliated Hospital of Guangzhou Medical University /ID# 275493, Guangzhou, Guangdong Shenzhen Eye Hospital /ID# 244001, Shenzhen, Guangdong Tongji Hospital Tongji Medical College of HUST /ID# 243998, Wuhan, Hubei Qingdao Eye Hospital Of Shandong First Medical University /ID# 243992, Qingdao, Shandong West China Hospital, Sichuan University /ID# 243999, Chengdu, Sichuan Tianjin Eye Hospital /ID# 243997, Tianjin, Tianjin Municipality The Second Affiliated Hospital of Zhejiang University School of Medicine /ID# 243996, Hangzhou, Zhejiang Zhongshan Ophthalmic Center,SunYat-Sen University /ID# 243843, Guangzhou